Vaccinex, Inc. Skyrocketed

Tue, Nov 10, 2020 at 05:30 PM

Vaccinex, Inc. (VCNX:NASDAQ) rocketted at $2.3, a gain of 26.4%. The stock appeared on our News Catalysts scanner on Tue 10 Nov 20 at 08:39 AM in the 'BIOTECH' category. From Mon 26 Oct 20, the stock recorded 30.00% Up Days and 27.27% Green Days

The stock spiked on Thu 17 Sep 20 at $6.61 with a volume of 6M+, and its share price has been moving sideways in recent weeks.

About Vaccinex, Inc. (VCNX:NASDAQ)

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.

Top 10 Gainers:

Greenland Technologies Holding Corporation (GTEC:NASDAQ), 120.51%
Summit Wireless Technologies, Inc. (WISA:NASDAQ), 70.42%
Revlon, Inc. (REV:NYSE), 47.24%
Trxade Group, Inc. (MEDS:NASDAQ), 41.86%
Inovio Pharmaceuticals, Inc. (INO:NASDAQ), 35.41%
Aptevo Therapeutics Inc. (APVO:NASDAQ), 35.37%
Team, Inc. (TISI:NYSE), 28.12%
Titan Pharmaceuticals, Inc. (TTNP:NASDAQ), 27.69%
Teligent, Inc. (TLGT:NASDAQ), 27.3%
Vaccinex, Inc. (VCNX:NASDAQ), 26.37%